Table 2.

Clinical studies on c-Met MAbs in the treatment of DSTs.

Conditions	Interventions	First posted	Number enrolled	Phase	NCT number	State	Status
Neoplasms	Drug:4mg/kg/15mg/kg/30mg/kg Onartuzumab	January 9, 2014	30	Phase 1	NCT02031731	China	Completed
Solid Tumor	Drug: Onartuzumab Drug: Bevacizumab Drug: Erlotinib	July 2, 2015	12	Phase 3	NCT02488330	France	Completed
Colorectal Cancer	Drug: 5-FU Drug:FOLFOX regimen	August 17, 2011	194	Phase 2	NCT01418222	United States	Completed
Gastric Cancer	Drug: 5-Fluoruracil Drug: Folinic acid Drug: Onartuzumab	August 10, 2012	564	Phase 3	NCT01662869	United States	Completed
Hepatocellular Carcinoma	Drug: Onartuzumab Drug: Sorafenib	July 11, 2013	9	Phase 1	NCT01897038	United States	Completed
Gastric Cancer	Drug: Onartuzumab Drug: Oxaliplatin	May 3, 2012	123	Phase 2	NCT01590719	United States	Completed
Solid Cancers	Drug: bevacizumab Drug:MetMAb(PRO143966)	February 17, 2010	44	Phase 1	NCT01068977	United States	Completed
Advanced Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Drug: Emibetuzumab Drug: Ramucirumab	March 10, 2014	97	Phase 1 Phase 2	NCT02082210	United States	Completed
Solid Tumor	Drug: Merestinib	September 30, 2016	12	Phase 2	NCT02920996	United States	Active, not recruiting

All clinicaltrials can be downloaded from www.clinicaltrials.gov (accessed February 28, 2022).